Science China Chemistry

, Volume 56, Issue 10, pp 1344–1350 | Cite as

The complexity of G-protein coupled receptor-ligand interactions

Reviews Special Topic Chemistry for Life Sciences
First Online:
Received:
Accepted:

Abstract

The G-protein coupled receptors (GPCRs) play fundamental roles in the human biololgy and drug discovery. GPCRs function as signalling molecules that transduce extracellular signals into cells. The signalling transduction is generally triggered by interacting with ligands, including photons, ions, small organic compounds, peptides, proteins and lipids. In this review, we focus on interactions with diffusible ligands such as hormones and neurotransmitters. We discuss three aspects of the complexity of the GPCR-ligand interactions: functional selectivity of ligands, receptor subtype selectivity of ligands and orphan GPCRs.

Keywords

G-protein coupled receptors (GPCR) ligand interaction functional selectivity receptor subtype 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tyndall JD, Sandilya R. GPCR agonists and antagonists in the clinic. Med Chem, 2005, 1: 405–421CrossRefGoogle Scholar
  2. 2.
    Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov, 2008, 7: 339–357CrossRefGoogle Scholar
  3. 3.
    Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Marzio PD, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature, 1996, 381: 661–666CrossRefGoogle Scholar
  4. 4.
    Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272: 872–877CrossRefGoogle Scholar
  5. 5.
    Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev, 2000, 21: 90–113CrossRefGoogle Scholar
  6. 6.
    Ruffolo RRJ, Hollinger MA, Eds. G-Protein Coupled Transmembrane Signaling Mechanisms. Boca Raton: CRC Press, 1998Google Scholar
  7. 7.
    Gershengorn MC, Osman R. Minireview: Insights into G Protein-coupled receptor function using molecular models. Endocrinology, 2001, 142: 2–10CrossRefGoogle Scholar
  8. 8.
    Luttrell LM. Transmembrane signaling by G protein-coupled receptors. Methods Mol Biol, 2006, 332: 3–49Google Scholar
  9. 9.
    Maudsley S, Martin B, Luttrell LM. The origins of diversity and specificity in G protein-coupled receptor signaling. J Pharmacol Exp Ther, 2005, 314: 485–494CrossRefGoogle Scholar
  10. 10.
    Kolakowski LF Jr. GCRDb: A G-protein-coupled receptor database. Receptors Channels, 1994, 2: 1–7Google Scholar
  11. 11.
    Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol, 2003, 63: 1256–1272CrossRefGoogle Scholar
  12. 12.
    Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Trong IL, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289: 739–745CrossRefGoogle Scholar
  13. 13.
    Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature, 2009, 459: 356–363CrossRefGoogle Scholar
  14. 14.
    Topiol S, Sabio M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochemical Pharmacology, 2009, 78: 11–20CrossRefGoogle Scholar
  15. 15.
    Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol, 2013, 53: 531–556CrossRefGoogle Scholar
  16. 16.
    Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, Wüthrich K. The GPCR Network: A large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov, 2013, 12: 25–34CrossRefGoogle Scholar
  17. 17.
    Hanson MA, Stevens RC. Discovery of new GPCR biology: One receptor structure at a time. Structure, 2009, 17: 8–14CrossRefGoogle Scholar
  18. 18.
    Audet M, Bouvier M. Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol, 2008, 4: 397–403CrossRefGoogle Scholar
  19. 19.
    Seifert R, Dove S. Functional selectivity of GPCR ligand stereoisomers: New pharmacological opportunities. Mol Pharmacol, 2009, 75: 13–18CrossRefGoogle Scholar
  20. 20.
    Woo AY, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW, Xiao RP. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol, 2009, 75: 158–165CrossRefGoogle Scholar
  21. 21.
    Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science, 2012, 335: 1106–1110CrossRefGoogle Scholar
  22. 22.
    Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther, 2007, 320: 1–13CrossRefGoogle Scholar
  23. 23.
    Zheng H, Loh HH, Law PY. Agonist-selective signaling of G protein-coupled receptor: Mechanisms and implications. IUBMB Life, 2010, 62: 112–119Google Scholar
  24. 24.
    Kenakin T. Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol, 2002, 42: 349–379CrossRefGoogle Scholar
  25. 25.
    Galandrin S, Oligny-Longpre G, Bouvier M. The evasive nature of drug efficacy: Implications for drug discovery. Trends Pharmacol Sci, 2007, 28: 423–430CrossRefGoogle Scholar
  26. 26.
    Gilchrist A, Blackmer T. Modulating G-protein-coupled receptors: From traditional pharmacology to allosterics. Trends in Pharmacological Sciences, 2007, 28: 431–437CrossRefGoogle Scholar
  27. 27.
    Wang T, Duan Y. Binding modes of CCR5-targetting HIV entry inhibitors: Partial and full antagonists. J Mol Graph Model, 2008, 26: 1287–1295CrossRefGoogle Scholar
  28. 28.
    Wang T, Duan Y. HIV co-receptor CCR5: Structure and interactions with inhibitors. Infect Disord Drug Targets, 2009, 9: 279–288CrossRefGoogle Scholar
  29. 29.
    Vogel R, Ludeke S, Siebert F, Sakmar TP, Hirshfeld A, Sheves M. Agonists and partial agonists of rhodopsin: Retinal polyene methylation affects receptor activation. Biochemistry, 2006, 45: 1640–1652CrossRefGoogle Scholar
  30. 30.
    Seifert R, Wenzel-Seifert K, Gether U, Kobilka BK. Functional differences between full and partial agonists: Evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther, 2001, 297: 1218–1226Google Scholar
  31. 31.
    Granier S, Kim S, Shafer AM, Ratnala VR, Fung JJ, Zare RN, Kobilka B. Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: Insights from fluorescence resonance energy transfer studies. J Biol Chem, 2007, 282: 13895–13905CrossRefGoogle Scholar
  32. 32.
    Yao X, Parnot C, Deupi X, Ratnala VR, Swaminath G, Farrens D, Kobilka B. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol, 2006, 2: 417–422CrossRefGoogle Scholar
  33. 33.
    Li JH, Han SJ, Hamdan FF, Kim SK, Jacobson KA, Bloodworth LM, Zhang X, Wess J. Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands. J Biol Chem, 2007, 282: 26284–26293CrossRefGoogle Scholar
  34. 34.
    Li JH, Hamdan FF, Kim SK, Jacobson KA, Zhang X, Han SJ, Wess J. Ligand-specific changes in M3 muscarinic acetylcholine receptor structure detected by a disulfide scanning strategy. Biochemistry, 2008, 47: 2776–2788CrossRefGoogle Scholar
  35. 35.
    Vilardaga JP, Steinmeyer R, Harms GS, Lohse MJ. Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol, 2005, 1: 25–28CrossRefGoogle Scholar
  36. 36.
    Kobilka BK, Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci, 2007, 28: 397–406CrossRefGoogle Scholar
  37. 37.
    Hoffmann C, Zurn A, Bunemann M, Lohse MJ. Conformational changes in G-protein-coupled receptors-the quest for functionally selective conformations is open. Br J Pharmacol, 2008, 153: S358–366CrossRefGoogle Scholar
  38. 38.
    Hill SJ. G-protein-coupled receptors: Past, present and future. Br J Pharmacol, 2006, 147: S27–37CrossRefGoogle Scholar
  39. 39.
    Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK. Structure and function of an irreversible agonist-beta2 adrenoceptor complex. Nature, 2011, 469: 236–240CrossRefGoogle Scholar
  40. 40.
    Rasmussen SG, Choi HJ, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, Schnapp A, Konetzki I, Sunahara RK, Gellman SH, Pautsch A, Steyaert J, Weis WI, Kobilka BK. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature, 2011, 469: 175–180CrossRefGoogle Scholar
  41. 41.
    Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC. Structure of an agonist-bound human A2A adenosine receptor. Science, 2011, 332: 322–327CrossRefGoogle Scholar
  42. 42.
    Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol, 2005, 144: 317–322CrossRefGoogle Scholar
  43. 43.
    Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology, 1999, 359: 7–10CrossRefGoogle Scholar
  44. 44.
    Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes—Characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369: 151–159CrossRefGoogle Scholar
  45. 45.
    Strosberg AD. Structure, function and regulation of the three betaadrenoceptor subtypes. In: Ruffolo RRJ, Hollinger MA, Eds. G-Protein Coupled Transmembrane Signaling Mechanisms. Boca Raton: CRC Press, 1998Google Scholar
  46. 46.
    Steinberg SF. The Molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res, 1999, 85: 1101–1111CrossRefGoogle Scholar
  47. 47.
    Frielle T, Daniel KW, Caron MG, Lefkowitz RJ. Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors. Proc Natl Acad Sci USA, 1988, 85: 9494–9498CrossRefGoogle Scholar
  48. 48.
    Sugimoto Y, Fujisawa R, Tanimura R, Lattion AL, Cotecchia S, Tsujimoto G, Nagao T, Kurose H. beta(1)-Selective agonist (−)-1-(3,4-dimethoxyphenetylamino)-3-(3,4-dihydroxy)-2-propanol [(−)-RO363] differentially interacts with key amino acids responsible for beta(1)-selective binding in resting and active states. J Pharmacol Exp Ther, 2002, 301: 51–58CrossRefGoogle Scholar
  49. 49.
    Marullo S, Emorine LJ, Strosberg AD, Delavier-Klutchko C. Selective binding of ligands to beta 1, beta 2 or chimeric beta 1/beta 2-adrenergic receptors involves multiple subsites. Embo J, 1990, 9: 1471–1476Google Scholar
  50. 50.
    Isogaya M, Sugimoto Y, Tanimura R, Tanaka R, Kikkawa H, Nagao T, Kurose H. Binding pockets of the beta 1- and beta 2-adrenergic receptors for subtype-selective agonists. Mol Pharmacol, 1999, 56: 875–885Google Scholar
  51. 51.
    Isogaya M, Yamagiwa Y, Fujita S, Sugimoto Y, Nagao T, Kurose H. Identification of a key amino acid of the beta 2-adrenergic receptor for high affinity binding of salmeterol. Mol Pharmacol, 1998, 54: 616–622Google Scholar
  52. 52.
    Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol, 1998, 53: 128–134Google Scholar
  53. 53.
    Alberts GL, Pregenzer JF, Im WB. Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. Mol Pharmacol, 1998, 54: 379–388Google Scholar
  54. 54.
    Schioth HB, Yook P, Muceniece R, Wikberg JE, Szardenings M. Chimeric melanocortin MC1 and MC3 receptors: Identification of domains participating in binding of melanocyte-stimulating hormone peptides. Mol Pharmacol, 1998, 54: 154–161Google Scholar
  55. 55.
    Kobayashi T, Kiriyama M, Hirata T, Hirata M, Ushikubi F, Narumiya S. Identification of domains conferring ligand binding specificity to the prostanoid receptor. J Biol Chem, 1997, 272: 15154–15160CrossRefGoogle Scholar
  56. 56.
    Leeb T, Mathis SA, Leeb-Lundberg LMF. The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists. J Biol Chem, 1997, 272: 311–317CrossRefGoogle Scholar
  57. 57.
    Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454: 486–491CrossRefGoogle Scholar
  58. 58.
    Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science, 2007, 318: 1266–1273CrossRefGoogle Scholar
  59. 59.
    Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein coupled receptor. Science, 2007, 318: 1258–1265CrossRefGoogle Scholar
  60. 60.
    Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454: 486–491CrossRefGoogle Scholar
  61. 61.
    Jager D, Schmalenbach C, Prilla S, Schrobang J, Kebig A, Sennwitz M, Heller E, Tränkle C, Holzgrabe U, Höltje HD, Mohr K. Allosteric small molecules unveil a role of an extracellular E2/transmembrane helix 7 junction for G protein-coupled receptor activation. J Biol Chem, 2007, 282: 34968–34976CrossRefGoogle Scholar
  62. 62.
    Thomas RL, Mistry R, Langmead CJ, Wood MD, Challiss RA. G protein coupling and signaling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists. J Pharmacol Exp Ther, 2008, 327: 365–374CrossRefGoogle Scholar
  63. 63.
    Antony J, Kellershohn K, Mohr-Andra M, Kebig A, Prilla S, Muth M, Heller E, Disingrini T, Dallanoce C, Bertoni S, Schrobang J, Tränkle C, Kostenis E, Christopoulos A, Höltje HD, Barocelli E, De Amici M, Holzgrabe U, Mohr K. Dualsteric GPCR targeting: A novel route to binding and signaling pathway selectivity. Faseb J, 2009, 23: 442–450CrossRefGoogle Scholar
  64. 64.
    Avlani VA, Gregory KJ, Morton CJ, Parker MW, Sexton PM, Christopoulos A. Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands. J Biol Chem, 2007, 282: 25677–25686CrossRefGoogle Scholar
  65. 65.
    Klco JM, Wiegand CB, Narzinski K, Baranski TJ. Essential role for the second extracellular loop in C5a receptor activation. Nat Struct Mol Biol, 2005, 12: 320–326CrossRefGoogle Scholar
  66. 66.
    Bokoch M, Zou Y, Rasmussen S, Liu C, Nygaard R, Rosenbaum DM, Fung JJ, Choi HJ, Thian FS, Kobilka TS, Puglisi JD, Weis WI, Pardo L, Prosser RS, Mueller L, Kobilka BK. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature, 2010, 463: 108–112CrossRefGoogle Scholar
  67. 67.
    Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V, Stevens RC. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 2010, 330: 1091–1995CrossRefGoogle Scholar
  68. 68.
    Wang T, Duan Y. Chromophore channeling in the G-protein coupled receptor rhodopsin. J Am Chem Soc, 2007, 129: 6970–6971CrossRefGoogle Scholar
  69. 69.
    Wang T, Duan Y. Retinal release from opsin in molecular dynamics simulations. J Mol Recognition, 2011, 24: 350–358CrossRefGoogle Scholar
  70. 70.
    Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta(2) adrenergic G-protein-coupled receptor. Nature, 2007, 450: 383–387CrossRefGoogle Scholar
  71. 71.
    Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein coupled receptor. Science, 2007, 318: 1258–1265CrossRefGoogle Scholar
  72. 72.
    Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, Stevens RC. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure, 2008, 16: 897–905CrossRefGoogle Scholar
  73. 73.
    Wang T, Duan Y. Ligand entry and exit pathways in the beta2-adrenergic receptor. J Mol Biol, 2009, 392: 1102–1115CrossRefGoogle Scholar
  74. 74.
    Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A, 2003, 100: 4903–4908CrossRefGoogle Scholar
  75. 75.
    Fredriksson R, Schioth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol, 2005, 67: 1414–1425CrossRefGoogle Scholar
  76. 76.
    Civelli O, Saito Y, Wang Z, Nothacker HP, Reinscheid RK. Orphan GPCRs and their ligands. Pharmacology & Therapeutics, 2006, 110: 525–532CrossRefGoogle Scholar
  77. 77.
    Chung S, Funakoshi T, Civelli O. Orphan GPCR research. Br J Pharmacol, 2008, 153: S339–S346CrossRefGoogle Scholar
  78. 78.
    Civelli O. Orphan GPCRs and neuromodulation. Neuron, 2012, 76: 12–21CrossRefGoogle Scholar
  79. 79.
    Civelli O. GPCR deorphanizations: The novel, the known and the unexpected transmitters. Trends Pharmacol Sci, 2005, 26: 15–19CrossRefGoogle Scholar
  80. 80.
    Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: Molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther, 2004, 103: 21–80CrossRefGoogle Scholar
  81. 81.
    Levoye A, Dam J, Ayoub MA, Guillaume JL, Jockers R. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep, 2006, 7: 1094–1098CrossRefGoogle Scholar
  82. 82.
    Levoye A, Jockers R. Alternative drug discovery approaches for orphan GPCRs. Drug Discov Today, 2008, 13: 52–58CrossRefGoogle Scholar
  83. 83.
    Kontijevskis A, Petrovska R, Mutule I, Uhlen S, Komorowski J, Prusis P, Wikberg JE. Proteochemometric analysis of small cyclic peptides’ interaction with wild-type and chimeric melanocortin receptors. Proteins, 2007, 69: 83–96CrossRefGoogle Scholar
  84. 84.
    Lapinsh M, Prusis P, Uhlen S, Wikberg JE. Improved approach for proteochemometrics modeling: application to organic compound—amine G protein-coupled receptor interactions. Bioinformatics, 2005, 21: 4289–4296CrossRefGoogle Scholar
  85. 85.
    Lapinsh M, Prusis P, Petrovska R, Uhlen S, Mutule I, Veiksina S, Wikberg JE. Proteochemometric modeling reveals the interaction site for Trp9 modified alpha-MSH peptides in melanocortin receptors. Proteins, 2007, 67: 653–660CrossRefGoogle Scholar
  86. 86.
    Strombergsson H, Prusis P, Midelfart H, Lapinsh M, Wikberg JE, Komorowski J. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions. Proteins, 2006, 63: 24–34CrossRefGoogle Scholar
  87. 87.
    Bock JR, Gough DA. Virtual screen for ligands of orphan G protein-coupled receptors. J Chem Inf Model, 2005, 45: 1402–1414CrossRefGoogle Scholar
  88. 88.
    Jiang Z, Zhou Y. Using silico methods predicting ligands for orphan GPCRs. Curr Protein Pept Sci, 2006, 7: 459–464CrossRefGoogle Scholar
  89. 89.
    Colette J, Ave E, Grenier-Boley B, Coquel AS, Lesellier K, Puget K. Bioinformatics-based discovery and identification of new biologically active peptides for GPCR deorphanization. J Pept Sci, 2007, 13: 568–574CrossRefGoogle Scholar
  90. 90.
    Jacob L, Hoffmann B, Stoven V, Vert JP. Virtual screening of GPCRs: An in silico chemogenomics approach. BMC Bioinformatics, 2008, 9: 363CrossRefGoogle Scholar
  91. 91.
    Wang T, Duan Y. Identification of G-protein coupled receptors and ligands interactions on a chemo-genomic scale. Computers and Applied Chemistry 2009, 26: 689–696Google Scholar

Copyright information

© Science China Press and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Genome CenterUniversity of CaliforniaDavisUSA

Personalised recommendations